Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Conditions
- Large B-cell Lymphoma
- Interventions
- Genetic: cemacabtagene ansegedleucelDevice: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
- Registration Number
- NCT06500273
- Lead Sponsor
- Allogene Therapeutics
- Brief Summary
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.
In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide.
Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 250
- LBCL per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma histologically confirmed by pathology report.
- Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) as intended. Participants cannot have received additional lines of therapy.
- Participant achieved CR, or PR suitable for observation, at the end of first line therapy based on PET/CT evaluation
- Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, is positive.
- Adult participants ≥18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- Adequate hematological, renal, hepatic, pulmonary, and cardiac function
- Non-hematologic toxicities related to prior therapy must be recovered to baseline or grade ≤1.
Key
- LBCL with history of central nervous system involvement, transformed from other malignancy (e.g., transformed follicular lymphoma or marginal zone lymphoma, Richter's transformation), or T-cell/histiocyte rich LBCL.
- Prior treatment with anti-CD19 targeted therapies.
- Anti-cancer treatment, including radiation, after end of treatment PET/CT and/or MRD testing is performed.
- Active and clinically significant autoimmune disease.
- Active systemic bacterial, fungal, or viral infections requiring systemic treatment.
- History of another primary malignancy or bone marrow disorder (e.g., myelofibrosis, smoldering multiple myeloma) within 3 years prior to enrollment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description cemacabtagene ansegedleucel cemacabtagene ansegedleucel Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide. cemacabtagene ansegedleucel Fludarabine Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide. cemacabtagene ansegedleucel Cyclophosphamide Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide. cemacabtagene ansegedleucel Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide. Observation Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ Participants do not receive any study treatments. They are observed as per the current standard of care.
- Primary Outcome Measures
Name Time Method Event-free survival per independent review committee assessment Up to 60 months
- Secondary Outcome Measures
Name Time Method Overall survival Up to 60 months Incidence and severity of adverse events and their relationship to cemacabtagene ansegedleucel and ALLO-647 Up to 60 months Adverse events, treatment emergent adverse events, serious adverse events, and adverse events of special interest evaluated by the investigator based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CRS and ICANS will be graded using ASTCT.
Incidence and severity of laboratory toxicities related to cemacabtagene ansegedleucel and ALLO-647 Up to 60 months Change from baseline value and NCI toxicity grading of laboratory values outside of normal ranges using CTCAE version 5.0.
Progression-free survival per independent review committee assessment Up to 60 months Minimal residual disease clearance Up to 60 months
Trial Locations
- Locations (53)
Banner MD Anderson Cancer Center
🇺🇸Gilbert, Arizona, United States
Alta Bates Summit Medical Center
🇺🇸Berkeley, California, United States
City of Hope
🇺🇸Duarte, California, United States
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
University of California, Los Angeles
🇺🇸Los Angeles, California, United States
University of California, Davis Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
University of California, San Diego
🇺🇸San Diego, California, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
Rocky Mountain Cancer Centers
🇺🇸Denver, Colorado, United States
Medical Oncology Hematology Consultants
🇺🇸Newark, Delaware, United States
Scroll for more (43 remaining)Banner MD Anderson Cancer Center🇺🇸Gilbert, Arizona, United StatesMatthew Ulrickson, MDPrincipal Investigator